The Fund will seek to achieve an above average rate of income combined with sound prospects for capital growth.
Name | % Net Assets |
---|---|
GlaxoSmithKline PLC | 6.7% |
GlaxoSmithKline PLC | 6.6% |
BP PLC | 6.2% |
Royal Dutch Shell PLC | 5.4% |
Legal & General Group PLC | 5.3% |
Reed Elsevier PLC | 4.9% |
Imperial Tobacco Group PLC | 4.5% |
Unilever PLC | 4.4% |
Imperial Tobacco Group PLC | 3.9% |
DS Smith PLC | 3.6% |
Key | % Net Assets |
---|---|
GlaxoSmithKline PLC | 6.7% |
GlaxoSmithKline PLC | 6.6% |
BP PLC | 6.2% |
Royal Dutch Shell PLC | 5.4% |
Other | 75.1% |
Date | 31-Oct-2024 |
---|---|
NAV | 64.36p |
Currency | GBP |
Change | -0.62p |
% | -0.95% |
YTD change | 2.66p |
YTD % | 4.31% |
Fund Inception | 08/05/2006 |
---|---|
Fund Manager | Leigh Harrison |
TER | 1.63 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | £2000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 3.75% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research